-+ 0.00%
-+ 0.00%
-+ 0.00%

Immutep Presents ePoster At European Society For Medical Oncology Congress 2026 For Its Eftilagimod Alfa In Combination With KEYTRUDA

Benzinga·10/23/2026 12:04:38

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage immunotherapy company targeting cancer and autoimmune diseases, today announced health-related quality of life (HRQoL) data from the investigator-initiated EFTISARC-NEO Phase II trial. The data are being presented in an ePoster at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23–27, 2026 in Madrid, Spain.

EFTISARC-NEO is evaluating eftilagimod alfa ("efti") in combination with KEYTRUDA® (pembrolizumab) and radiotherapy in the neoadjuvant treatment of patients with resectable soft tissue sarcoma (STS). HRQoL is a secondary endpoint of the trial, and these findings build on the previously reported primary endpoint result in which the combination achieved a median 51.5% tumour hyalinization/fibrosis in the evaluable population (N=38), significantly exceeding the prespecified 35% target (p<0.001).